Wyeth abandons women's health in R&D cuts
This article was originally published in Scrip
Executive Summary
Wyethhas halved the number of therapeutics areas and diseases it will target in an overhaul of its R&D operations. In an internal announcement to employees yesterday, the firm said that it would concentrate on six therapeutic areas and 27 diseases to speed up drugs reaching the market and to improve profits.